<DOC>
	<DOCNO>NCT01259297</DOCNO>
	<brief_summary>This study plan provide new information regard role aliskiren ( without additional therapy diuretic Calcium channel blocker ( CCB ) ) elderly individual ( ≥ 65 year ) systolic blood pressure ( SBP ) 130 159 mmHg , prevent major cardiovascular ( CV ) event global measure physical , executive cognitive function .</brief_summary>
	<brief_title>A Randomized Controlled Trial Aliskiren Prevention Major Cardiovascular Events Elderly People</brief_title>
	<detailed_description>This 2x2 factorial design study 2 stratum . As per protocol , first co- Primary analysis well secondary analysis aliskiren base regimen v non-aliskiren base regimen . All aliskiren base arm combine aliskiren base regimen non-aliskiren base arm combine non-aliskiren base regimen .</detailed_description>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Systolic blood pressure 130 159 mmHg one following ( 1 , 2 3 ) : 1 . Men woman age ≥ 65 year least one following : ( secondary prevention ) Coronary heart disease Previous myocardial infarction Stable angina unstable angina document multivessel coronary artery disease , &gt; 50 % stenosis least 2 major coronary artery coronary angiography , positive stress test ( ECG nuclear perfusion scintogram ) , Multivessel PCI , Multivessel CABG surgery &gt; 4 year prior inform consent , recurrent angina ischemia follow surgery Stroke/TIA Previous document stroke document TIA &lt; 1 year inform consent Peripheral artery disease Previous limb bypass surgery percutaneous transluminal angioplasty , Previous limb foot amputation , History intermittent claudication , ankle : arm BP ratio ≤ 0.80 least one side , significant peripheral artery stenosis ( &gt; 50 % ) document angiography noninvasive test Diabetes mellitus : Highrisk diabetic evidence endorgan damage 2 . Men woman age ≥ 65 year history CVD , least 1 CV risk factor ( primary prevention ) : History dyslipidemia , define LDL cholesterol &gt; 3.5 mmol/L ( 135 mg/dL ) HDL &lt; 1.3 mmol/L ( 50 mg/dL ) woman &lt; 1.0 mmol/L ( 39 mg/dL ) men total cholesterol/HDL ratio &gt; 5 History current recent smoking ( regular tobacco use within 5 year ) Abdominal adiposity define waist/hip ratio ≥ 0.90 woman ≥ 0.95 men History dysglycemia define impaired fasting glucose ( IFG fast plasma glucose 5.6 6.9 mmol/L [ 101 124 mg/dL ] ) , impair glucose tolerance ( IGT fast plasma glucose &lt; 7 mmol/L [ 126 mg/dL ] 2 hour glucose 7.8 11.0 mmol/L [ 140 198 mg/dL ] ) type 2 diabetes Renal dysfunction : eGFR &lt; 60 ml/min/1.73m2 &gt; 30 ml/min/1.73m2 ( MDRD formula ) and/or microalbuminurea/macroalbuminurea Clinical evidence leave ventricular hypertrophy 3 . Men woman age ≥ 70 year ( primary prevention ) 1 . Current treatment aliskiren , ACEinhibitor , ARB aldosterone antagonist unable discontinue therapy without clinical vascular disease . Individuals CVD type 2 diabetes and/or renal dysfunction may receive ACEinhibitor ARB , , contraindication Aliskiren , Amlodipine Hydrochlorothiazide . 2 . Use thiazide diuretic amlodipine another calcium channel blocker . Patients one two class drug eligible 3 . Uncontrolled hypertension ( systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg ) 4 . Symptomatic heart failure , require use loop diuretic 5 . Hemodynamically significant primary valvular outflow tract obstruction ( e.g . aortic mitral valve stenosis , asymmetric septal hypertrophy , malfunction prosthetic valve ) . Constrictive pericarditis . Complex congenital heart disease . 6 . Acute stroke &lt; 3 month TIA ≤ 7 day inform consent , acute coronary syndrome &lt; 1 month inform consent 7 . Planned cardiac surgery angioplasty &lt; 3 month inform consent procedure &lt; 3 month inform consent 8 . Severe renal impairment eGFR ≤ 30 ml/min/1.73m2 ( MDRD formula ) ; know renal artery stenosis ; serum potassium ≥ 5.3 mmol/L 9 . Chronic liver disease ( i.e . cirrhosis , esophageal varix , portocaval shunt persistent hepatitis ) abnormal liver function , i.e. , alanine transaminase ( ALT ) AST &gt; 3x upper limit normal ( ULN ) 10 . Concurrent treatment cyclosporine quinidine ; chronic use nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX 2 ) inhibitor patient eGFR &lt; 60 ml/min/1.73m2 ( MDRD formula ) 11 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year regardless whether evidence local recurrence metastases 12 . Other serious condition ( ) likely interfere study participation ability complete study . Significant psychiatric illness , senility , dementia , alcohol substance abuse , could impair ability provide inform consent adhere study procedure</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Aliskiren</keyword>
	<keyword>Elderly</keyword>
	<keyword>Major Cardiovascular Events</keyword>
	<keyword>Effect aliskiren-based regimen major CV event ( composite CV death , non-fatal MI , non-fatal stroke significant heart failure ) elderly</keyword>
</DOC>